SwedClone Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

SwedClone General Information

Description

Operator of a biotechnology company intended to specialize in generation of monoclonal antibodies. The company provide a complete immunology service where antibodies can be raised against customer-supplied antigens or synthesized peptides on demand, enabling customers to receive antibodies having the desired properties.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • Uminova Science Park
  • Box 7964
  • 907 19 Umeaa
  • Sweden
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Uminova Science Park
  • Box 7964
  • 907 19 Umeaa
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SwedClone Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 13-Jan-2022 Completed Out of Business
1. Accelerator/Incubator Completed Startup
To view SwedClone’s complete valuation and funding history, request access »

SwedClone FAQs

  • When was SwedClone founded?

    SwedClone was founded in 2008.

  • Where is SwedClone headquartered?

    SwedClone is headquartered in Umeaa, Sweden.

  • What industry is SwedClone in?

    SwedClone’s primary industry is Biotechnology.

  • Is SwedClone a private or public company?

    SwedClone is a Private company.

  • What is SwedClone’s current revenue?

    The current revenue for SwedClone is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »